Antibiotics developer MGB Biopharma's lead candidate exploits University of Strathclyde research, and it has just raised an undislcosed amount of new capital.
MGB Biopharma, a UK-based antibiotics developer based on University of Strathclyde’s research, raised an undisclosed amount on Friday in a round led by syndicate Archangel Investors.
The oversubscribed round also featured Scottish Investment Bank (SIB), part of state economic development agency Scottish Enterprise, as well as venture capital firm Barwell and angel group TRI Capital.
Founded in 2010, MGB is working on an oral antibiotic called MGB-BP-3 as a treatment for clostridium difficile bacteria, including a particularly virulent…
